MEET THE BOARD OF DIRECTORS

Dr. Selick has served on our board of directors since February 2009. He is currently Chief Executive Officer and board member of Hinge Bio, Inc., a private biotechnology company focused on developing therapeutics for patients living with cancer. He previously served as Vice Chancellor of Business Development, Innovation and Partnerships at the University of California, San Francisco, from April 2017 to December 2022. Dr. Selick was a Venture Partner at Mission Bay Capital, a venture capital firm, from 2018 until his resignation at the end of 2022. Previously, he was the Chief Executive Officer of Threshold Pharmaceuticals, Inc., a biotechnology company, from June 2002 until the company’s merger with Molecular Templates Inc. in April 2017. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company, which was acquired two years after its founding. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. Dr. Selick serves as Chairman of the board of directors of Molecular Templates, Inc. (Nasdaq: MTEM), a biopharmaceutical company. Dr. Selick previously served as Lead Director and then Chairman of PDL BioPharma, Inc., a biopharmaceutical company, from 2009 to December 2019, and served as Chairman of the board of directors of Threshold Pharmaceuticals, Inc. until it merged with Molecular Templates Inc. in April 2017. Dr. Selick received a B.A. in Biophysics and a Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Mr. Giraudo has served on our board of directors since May 2018. He has served as both Chief Financial Officer and Chief Operating Officer of Gossamer Bio, Inc. (Nasdaq: GOSS), a biotechnology company, since September 2021, and as Gossamer’s Chief Financial Officer since May 2018. Prior to joining Gossamer Bio, Mr. Giraudo was a Senior Managing Director at Leerink Partners from 2009 to April 2018, where he was responsible for their western North America and Asia Pacific biotechnology and medical technology banking practice. Before joining Leerink, he was a Managing Director with Merrill Lynch and Co.’s Global Healthcare Investment Banking Group. Mr. Giraudo joined Merrill Lynch in 1997. As a banker, he completed over 200 corporate finance, corporate partnership and strategic advisory transactions. Mr. Giraudo has been a member of the board of directors of Valerio Therapeutics, S.A. (EPA: ALVIO), a biotechnology company, since November 2021. He received a B.A. from Georgetown University.

Ms. O’Dowd has served as a member of our board of directors since August 2020. Ms. O’Dowd is also a member of the board of directors of Ichor Holdings, Ltd. (Nasdaq: ICHR), a leader in the design, engineering and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment, and is a director of the Independent Institute, a non-profit, non-partisan, public policy research and communications organization. From September 2008 until her retirement in March 2020, she was Senior Vice President and Chief Legal Officer at Lam Research Corporation (Nasdaq: LRCX), an S&P 500 technology company. From 2009 to 2012 she also served as Group Vice President of Human Resources at Lam. From February 2007 to September 2008, she served as Vice President of FibroGen, Inc. (Nasdaq: FGEN), a biopharmaceutical company. Ms. O’Dowd received a J.D. from Stanford Law School, an M.A. in Communications from Stanford University and an A.B. in Mathematics from Immaculata College.

Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist Therapeutics since December 2008. He has 38 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a $1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. He received his Ph.D. in Chemistry from Rutgers University, New Jersey and his M.Sc. and B.Sc. in Chemistry from S. P. University, Vallabh Vidyanagar, India.

Mr. Swisher joined has served as a member of our board of directors since October 2023. He served as President of Jazz Pharmaceuticals (Nasdaq: JAZZ) from January 2018 until September 2023, and also as its Chief Operating Officer from January 2018 until May 2021 and from November 2022 until September 2023. At Jazz, Mr. Swisher played an instrumental role in doubling the company’s product revenues since 2018, expanding its research and development pipeline and executing significant corporate development transactions. Prior to Jazz, where Mr. Swisher will serve as a strategic advisor through March 2024, he served as the President and Chief Executive Officer of Sunesis Pharmaceuticals from 2003 to 2017. There, he led the evolution of Sunesis from its early-stage chemistry platform to a multi-asset development portfolio. Earlier in his career, Mr. Swisher served as Senior Vice President of Sales and Marketing at ALZA Corporation, contributing to its impressive growth leading up to its acquisition by Johnson & Johnson. Mr. Swisher is also a member of the Board of Directors at Corcept Therapeutics (Nasdaq: CORT) and Chairman of the Board of Cerus Corporation (Nasdaq: CERS). He earned a B.A. from Yale University and an M.B.A. from Stanford University.